Literature DB >> 30719117

Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients.

Xue Yang1,2, Shuangshuang Li1,2, Huiju Wang1,3, Wanyuan Chen4, Xiaozhou Mou1,2, Shibing Wang1,2.   

Abstract

The coxsackie and adenovirus receptor (CAR), a tumor suppressor, is vital for the effectiveness of therapies which utilize the adenovirus. However, studies on CAR expression in hepatocellular carcinoma (HCC) are conflicting and its clinical significance requires exploration. In this study, immunohistochemistry has been carried out on tissue microarrays consisting of 198 pairs of HCC and neighboring healthy tissue specimens from Chinese Han patients to evaluate CAR expression. Relative to normal tissues, decreased CAR expression (56% vs. 57%; P>0.05) was detected in HCC samples. CAR immunopositivity in tumors was not dependent upon sex, age, tumor dimensions, differentiation, TNM stage or metastasis in HCC patients; however, positive expression was observed in 56% of the samples from patients with hepatic metastasis, which was the same as those devoid of metastasis (56%; P=0.042). Furthermore, survival analysis confirmed that the expression of CAR revealed no correlation with the prognosis. It was established that CAR exerted complex effects during liver tumorigenesis, potentially based on the stage of the cancer. Therefore, CAR expression analysis has to be carried out prior to adenoviral oncolytic therapy to stratify the patients.

Entities:  

Keywords:  Chinese Han patients; adenovirus; coxsackie and adenovirus receptor; immunohistochemistry; liver cancer

Year:  2018        PMID: 30719117      PMCID: PMC6350183          DOI: 10.3892/ol.2018.9868

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  Cell type- and region-dependent coxsackie adenovirus receptor expression in the central nervous system.

Authors:  Annette Persson; Xiaolong Fan; Bengt Widegren; Elisabet Englund
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

3.  Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape.

Authors:  Robert W Walters; Paul Freimuth; Thomas O Moninger; Ingrid Ganske; Joseph Zabner; Michael J Welsh
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

4.  Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer.

Authors:  Kazumasa Matsumoto; Shahrokh F Shariat; Gustavo E Ayala; Katherine A Rauen; Seth P Lerner
Journal:  Urology       Date:  2005-08       Impact factor: 2.649

5.  Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.

Authors:  Y Saito; M Sunamura; F Motoi; H Abe; S Egawa; D G Duda; T Hoshida; S Fukuyama; H Hamada; S Matsuno
Journal:  Cancer Gene Ther       Date:  2006-03       Impact factor: 5.987

6.  The Coxsackie-adenovirus receptor has elevated expression in human breast cancer.

Authors:  T A Martin; G Watkins; W G Jiang
Journal:  Clin Exp Med       Date:  2005-10       Impact factor: 3.984

7.  Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers.

Authors:  Yong Wang; Shizhong Wang; Yongyi Bao; Cheng Ni; Naifu Guan; Jianzhong Zhao; Leif G Salford; Bengt Widegren; Xiaolong Fan
Journal:  J Mol Histol       Date:  2006-09-22       Impact factor: 2.611

8.  The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.

Authors:  T A Martino; M Petric; H Weingartl; J M Bergelson; M A Opavsky; C D Richardson; J F Modlin; R W Finberg; K C Kain; N Willis; C J Gauntt; P P Liu
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

9.  Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies.

Authors:  H S Pandha; L H Stockwin; J Eaton; I A Clarke; A G Dalgleish; S M Todryk; G E Blair
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

10.  A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Authors:  Yaohe Wang; Stephen Thorne; Joseph Hannock; Jennelle Francis; Tina Au; Tony Reid; Nick Lemoine; David Kirn; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

View more
  2 in total

Review 1.  Decoding the mechanism of vascular morphogenesis to explore future prospects in targeted tumor therapy.

Authors:  Gayathri Venkatakrishnan; Venkatachalam Deepa Parvathi
Journal:  Med Oncol       Date:  2022-08-29       Impact factor: 3.738

Review 2.  Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Authors:  Selas T F Bots; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.